Dashboard
Manage Tickers

NKTX Nkarta, Inc.

Nasdaq nkartatx.com


$ 2.30 $ -0.19 (-7.63 %)    

Friday, 17-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 2.3
$ 2.47
$ 2.28 x 50
$ 2.60 x 500
$ 2.27 - $ 2.47
$ 1.31 - $ 4.55
999,107
na
163.36M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-20-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/28/2025 21:06:27

stifel-maintains-buy-on-nkarta-lowers-price-target-to-12
Stifel Maintains Buy on Nkarta, Lowers Pri...
08/14/2025 11:52:59

Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $14 to $12.

needham-reiterates-buy-on-nkarta-maintains-10-price-target
Needham Reiterates Buy on Nkarta, Maintain...
08/13/2025 10:04:36

Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $10 price target.

nkarta-q2-eps-031-beats-037-estimate
Nkarta Q2 EPS $(0.31) Beats $(0.37) Estimate
08/12/2025 20:16:54

Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.37) by 15....

mizuho-maintains-outperform-on-nkarta-lowers-price-target-to-14
Mizuho Maintains Outperform on Nkarta, Low...
06/10/2025 14:14:29

Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price target from $16 to $14.

nkarta-downgraded-analyst-cites-competitive-pressure-in-autoimmune-space
Nkarta Downgraded, Analyst Cites Competiti...
05/15/2025 19:46:39

Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and ma...

this-alcoa-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday
This Alcoa Analyst Is No Longer Bullish; H...
05/15/2025 12:04:25

needham-maintains-buy-on-nkarta-lowers-price-target-to-10
Needham Maintains Buy on Nkarta, Lowers Pr...
05/15/2025 11:25:11

Needham analyst Gil Blum maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $11 to $10.

william-blair-downgrades-nkarta-to-market-perform
William Blair Downgrades Nkarta to Market ...
05/15/2025 11:23:38

William Blair analyst Sami Corwin downgrades Nkarta (NASDAQ:NKTX) from Outperform to Market Perform.

nkarta-q1-eps-043-beats-044-estimate
Nkarta Q1 EPS $(0.43) Beats $(0.44) Estimate
05/14/2025 20:07:20

Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.2...

needham-reiterates-buy-on-nkarta-maintains-11-price-target
Needham Reiterates Buy on Nkarta, Maintain...
04/09/2025 12:01:57

Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/27/2025 17:05:46

why-is-autoimmune-disease-focused-nkarta-stock-trading-higher-on-thursday
Why Is Autoimmune Disease Focused Nkarta S...
03/27/2025 16:50:30

Nkarta restructures to extend its cash runway into 2029, with upcoming NKX019 clinical data readouts in H2 2025. Analysts maint...

stifel-maintains-buy-on-nkarta-lowers-price-target-to-14
Stifel Maintains Buy on Nkarta, Lowers Pri...
03/27/2025 12:17:15

Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $15 to $14.

needham-reiterates-buy-on-nkarta-maintains-11-price-target
Needham Reiterates Buy on Nkarta, Maintain...
03/27/2025 11:19:54

Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.

hc-wainwright--co-reiterates-buy-on-nkarta-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on Nkar...
03/27/2025 10:44:27

HC Wainwright & Co. analyst Emily Bodnar reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $18 price target.

nkarta-q4-2024-gaap-eps-035-beats-041-estimate
Nkarta Q4 2024 GAAP EPS $(0.35) Beats $(0....
03/26/2025 20:23:01

Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 14....

nkarta-13g-filing-shows-citadel-advisors-reported-a-54-stake-in-the-co-as-of-december-6-2024
Nkarta 13G Filing Shows Citadel Advisors R...
12/13/2024 22:10:48

- SEC Filing

nkarta-announced-the-opening-of-ntrust-2-to-enrollment-and-the-ind-clearance-for-an-investigator-sponsored-trial-that-will-evaluate-nkx019-for-myasthenia-gravis-clinical-data-from-ntrust-1-and-ntrust-2-planned-for-2025
Nkarta Announced The Opening Of Ntrust-2 T...
12/05/2024 11:11:20

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts...

mizuho-maintains-outperform-on-nkarta-lowers-price-target-to-16
Mizuho Maintains Outperform on Nkarta, Low...
11/21/2024 13:14:11

Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price target from $20 to $16.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION